Tag Archives: Endpoints

Canadian biopharma Zymeworks files for $75 million IPO; name may sound funky but gameplan dead serious

Biopharmaceutical company Zymeworks Inc. (Vancouver BC) on Monday (April 3, 2107) said it has filed with the US Securities and Exchange Commission for an initial public offering. The company, which… Read more »

Indy’s Eli Lilly making noise with cancer push; Brickyard neighbor revving its drug-discovery engine

I’ve been to the headquarters of Eli Lilly & Co.–about 15 minutes (or about 5 miles) from the “Brickyard” where the Indianapolis 500 is run each year. The racing is… Read more »

Week’s opening stock salvo: Esperion, Nektar, CytomX soar; Aevi Genomic thrashed

Esperion Therapeutics Inc. (Nasdaq: ESPR) stock recently recovered big time from last Amgen-induced beat down to touch an 18-month high after the company outlined its path to FDA approval for its… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »